News
-
-
PRESS RELEASE
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies
OBI Pharma showcases advancements in ADC technology at AACR 2026, highlighting GlycOBI platform. Poster presentations feature OBI-902, OBI-904, OBI-201, OBI-221, and novel Obrion technology